May 27, 2025 — CeleCor Therapeutics has completed its multinational Phase 3 clinical trial of DisaggproT (zalunfiban), an investigational heart-attack drug designed for rapid use at first point of medical contact – including before patients reach the hospital.

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities with long-term economic or social challenges still face barriers to cutting-edge therapies such as gene editing, according to a 2020 American Heart Association presidential advisory.

May 22, 2025 — Auxira Health has officially launched — the company provides a new approach to clinical support purpose-built for cardiology. Auxira’s hybrid care model deploys expert clinical teams that virtually embed directly in a practice's existing workflows, freeing cardiologists to deliver care at the top of their experience while expanding access for patients.

May 21, 2025 — Corify Care recently announced it has entered into a know-how agreement with Mayo Clinic. Corify Care is an AI-driven medical technology company specializing in global cardiac mapping and real-time precision guidance for the treatment of cardiac arrhythmias.

May 21, 2025 – Johnson & Johnson MedTech has announced the U.S. launch of the Soundstar Crystal Ultrasound Catheter for intracardiac echocardiography (ICE) imaging in cardiac ablation procedures.  

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint results of EMPOWER CAD, the first prospective, real-world percutaneous coronary intervention (PCI) study in female patients with complex, calcified coronary artery disease. The favorable results confirm the results of earlier retrospective analyses demonstrating the benefits of coronary intravascular lithotripsy (IVL) in female patients. The results were presented in a late-breaking presentation at the annual EuroPCR meeting in Paris. 

May 15, 2025 — Abundant Venture Partners has launched the Abundant Platform to grow high value, sustainable companies that benefit healthcare provider organizations. The platform accelerates commercialization through the Abundant Venture Studio, ensures rapid adoption via the Abundant Alliance of healthcare providers, and drives scale with aligned, provider-backed seed and series A venture funds.

May 21, 2025 — RapidAI recently announced new study findings that show RapidAI’s clinically deep algorithms deliver superior accuracy in detecting medium vessel occlusions (MeVOs).

The data, presented as a late-breaking abstract at the European Stroke Organisation Conference (ESOC) 2025, analyzed 1,591 consecutive stroke cases at a comprehensive stroke center. Of the 1,122 eligible cases, RapidAI detected 93% (109) of MeVOs using CT Perfusion alone, compared to 70% (82) by Viz.ai.

May 20, 2025 — Royal Philips has launched  the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. The first patient in the study was enrolled at Aarhus University Hospital, Denmark.

May 19, 2025 — Gradient Denervation Technologies recently announced the company’s pulmonary denervation system has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This program creates an expedited review pathway for devices that have the potential to provide more effective treatment for life-threatening or debilitating conditions and meet FDA’s rigorous standards for safety and efficacy.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now